The DOI matches its Crossref record.
MALAT1 promotes the colorectal cancer malignancy by increasing DCP1A expression and miR203 downregulation
Abstract
The long non‐coding RNA MALAT1 has been proved to promote the cell proliferation, drug resistance, invasion, and metastasis of colorectal cancer (CRC) in vitro and in vivo by regulating the expression of various oncogenes and their protein products. Our previous work discovered that the expression of the mRNA‐decapping enzymes 1a (DCP1A) is upregulated in CRCs. However, the relationships between MALAT1 and DCP1A in the development of CRC and the underlying mechanisms are still unclear. In this study, we investigated the molecular mechanisms by which MALAT1 and DCP1A may be linked to contribute to the malignancies of CRCs. We found that DCP1A is a direct target molecule of MALAT1. Moreover, by screening the downstream genes of MALAT1, we noticed that microRNA 203(miR203), an oncogene suppressor in numerous cancers, is inversely correlated to both MALAT1 and DCP1A expressions. Following MALAT1 knockdown, we observed overexpression of miR203 accompanied with DCP1A downregulation to a level that reversed the promoted cell proliferation, invasion, and migration in vitro and in vivo, which could be restored by miR203 knockdown or DCP1A overexpression. These results proposed a new molecular mechanism of MALAT‐miR203‐DCP1A axis which is involved with the development and contributes to the malignancy of colorectal cancers.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and is considered a potential therapeutic target for colon cancer.”
From Targeted Nano-Drug Delivery of Colchicine against Colon Cancer Cells by Means of Mesoporous Silica Nanoparticles (2020) · cites this paper as [82]
In the citing paper
“Importantly, MALAT1 has been shown in several studies to promote colorectal cancer cell development via proliferation, migration, and invasion [81,82], and is considered a potential therapeutic target for colon cancer.”
From Targeted Nano-Drug Delivery of Colchicine against Colon Cancer Cells by Means of Mesoporous Silica Nanoparticles (2020) · cites this paper as [82]
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 46
- 10.1002/jcp.24918 · DOI
- 10.1007/s12253-015-9960-5 · DOI
- 10.1002/ijc.28557 · DOI
- 10.1186/1471-2164-14-589 · DOI
- 10.1016/j.humpath.2009.09.019 · DOI
- 10.1016/j.cellsig.2017.04.020 · DOI
- 10.18632/oncotarget.16339 · DOI
- 10.1016/j.canlet.2017.05.024 · DOI
- 10.1371/journal.pone.0049783 · DOI
- 10.1371/journal.pone.0061697 · DOI
- 10.1371/journal.pone.0123223 · DOI
- 10.1097/CMR.0000000000000406 · DOI
- 10.1002/ijc.30409 · DOI
- Qiao L, 2017, Down regulation of the long non‐coding RNA PCAT‐1 induced growth arrest and apoptosis of colorectal cancer cells, Life Sci, 38, 257
- 10.1007/s10529-017-2392-4 · DOI
- Zhu W, 2017, Knockdown of lncRNA HNF1A‐AS1 inhibits oncogenic phenotypes in colorectal carcinoma, Mol Med Rep, 12, 6626
- 10.1016/j.biopha.2017.07.056 · DOI
- Peng WX, 2017, LncRNA‐mediated regulation of cell signaling in cancer, Oncogene, 27, 4615
- 10.1111/cpr.12312 · DOI
- 10.1016/j.brainresbull.2017.03.010 · DOI
- 10.1111/jcmm.13101 · DOI
- 10.1080/15384101.2017.1361072 · DOI
- 10.1016/j.celrep.2017.08.041 · DOI
- 10.1038/s41598-017-10869-y · DOI
- 10.1159/000480419 · DOI
- He B, 2017, LncRNA SNHG5 regulates imatinib resistance in chronic myeloid leukemia via acting as a CeRNA against MiR‐205‐5p, Am J Cancer Res, 7, 1704
- 10.1038/sj.onc.1207219 · DOI
- 10.1016/j.biopha.2017.07.005 · DOI
- 10.1002/gcc.22332 · DOI
- 10.1177/1010428317719869 · DOI
- 10.1038/modpathol.2017.35 · DOI
- 10.1371/journal.pone.0073268 · DOI
- 10.1016/j.scr.2013.09.011 · DOI
- 10.1158/1535-7163.MCT-16-0591 · DOI
- Jin Y, 2017, LncRNA MALAT1 promotes proliferation and metastasis in epithelial ovarian cancer via the PI3K‐AKT pathway, Eur Rev Med Pharmacol Sci, 21, 3176
- 10.3390/ijms16046677 · DOI
- 10.1002/ijc.30409 · DOI
- 10.1371/journal.pone.0061697 · DOI
- 10.1371/journal.pone.0049783 · DOI
- 10.1111/jcmm.12940 · DOI
- 10.1016/j.molimm.2015.01.019 · DOI
- 10.1016/j.taap.2014.04.020 · DOI
- 10.3892/ijo.2014.2365 · DOI
- 10.3892/mmr.2015.4013 · DOI
- Liang M, 2015, Downregulation of miR203 induces overexpression of PIK3CA and predicts poor prognosis of gastric cancer patients, Drug Des Devel Ther, 9, 3607
- 10.1158/1535-7163.MCT-16-0591 · DOI
Cited by
Sorted by citations
AbouAitah, K., Hassan, H. A., Swiderska-Sroda, A., Gohar, L., Shaker, O. G., Wojnarowicz, J., Opalinska, A., Smalc-Koziorowska, J., Gierlotka, S., & Lojkowski, W. (2020) · Cancers · doi:10.3390/cancers12010144 · Cited by 105
Metadata
- Authors
- Wu, C., Zhu, X., Tao, K., Liu, W., Ruan, T., Wan, W., Zhang, C., & Zhang, W.
- Affiliations
- Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan China
- Department of Hematology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan China
- ORCID
- Zhang, Weikang
- Venue
- Molecular Carcinogenesis
- Publisher
- Wiley
- Published
- 2018-07-12
- Volume
- 57
- Issue
- 10
- Pages
- 1421-1431
- ISSN
- 0899-1987
- 1098-2744
- Cited by
- 45
- References
- 0
- Language
- en
- Funders
- Natural Science Foundation of Hubei Province (2017CFB474)
- National Natural Science Foundation of China (81600401)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review